ACTIPATCH WILL BE A "STANDARD OF CARE" PRODUCT! With FDA

New Post Public Reply Private Reply Replies (0) Message Board
Bielionaire
215
ACTIPATCH WILL BE A "STANDARD OF CARE" PRODUCT!
With FDA clearance for treatment of knee, back, wrist, hips, ankles, plantar fasciitis and all musculoskeletal pain, how can it not, especially at the low price of $35 - with a much longer battery life than the competition! The Actipatch FDA clearance allows it to be sold over the counter (without a prescription). The RecoveryRX applications (post operative pain, edema, wound care, etc.) do require a doctor order. Add in RecoveryRx-Veterinary and you have over 10 billion potential repeat customers - every adult and pet on the planet (every month). Then there is the "wellness" market, as many people use Actipatch for Restless Leg Syndrome (RLS is estimated to affect 10% of adults worldwide), menstrual pain, migraines and other "off label" aches and pains.

POTENTIAL
The potential is mind-boggling - especially if Actipatch is identified as a "wellness product" for the applications not currently covered by the FDA clearances.

From the 2024 Annual Report:
BioElectronics is an electroceutical company that develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. Our innovative pulsed shortwave therapy technology (PSWT) that uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. The neuromodulation basis of PSWT presents significant opportunities for BioElectronics to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications.

The chronic pain market is larger than diabetes, heart disease, and cancer combined, with 20% of adults globally suffering from chronic pain. ActiPatch addresses the unmet need for 1.5 billion worldwide chronic pain sufferers. The Company’s medical devices modulate the body’s nerve activity to dampen the pain perception, which reduces drug use. RecoveryRx will be an ideal choice in reducing postoperative pain and exposure to long-term effects of opioid/NSAID therapy.

The technology has the potential to become the standard of care throughout the healthcare continuum across the OTC and healthcare markets. BioElectronics’ technology offers significant opportunities in menstrual pain, heel pain, migraine headaches, diabetic neuropathy, postoperative surgery, chronic wounds, bone growth stimulation, and other applications.

In February 2020, BioElectronics obtained a new 510(k) clearance from the U.S. FDA, granting over-the-counter marketing clearance for the drug-free ActiPatch medical device, to cover all musculoskeletal pain complaints. This paves the way for new products to treat all medical claims for musculoskeletal pain, including in the back, knee, hips, wrists, elbow, and ankle.

RECOVERYRX-VETERINARY COULD/SHOULD BE A GOLDMINE!
The Assisi Loop sells over 300/month just on Amazon @ $329, with 1/20 the battery life. Assisi Loop customers are paying the equivalent of over $6,000 when you factor in the additional cost and lower battery life, but Assisi customers seem happy to pay it based on the numerous 5-star reviews. RecoveryRx/Veterinary should be sold as a two/pack - one for the vagus nerve and the other for the area of pain.

BioElectronics Corporation (BIEL) Stock Research Links

BIEL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Join Regency Centers for Upcoming Earnings Conference Call

Updated Category News Views 106

Join Regency Centers for the Earnings Call Regency Centers Corporation invites all interested parties to participate in its earnings conference call following the release of its second quarter results. The Company is scheduled to announce its earnings results, providing valuable insights into its operational performance and strategic initiatives. Details of the Earnings...

Continue Reading
Unlocking the Secrets of Affordable Air Travel in 2025

Updated Category News Views 154

Expedia's 2025 Air Hacks Report Reveals Savings Tips Expedia® has unveiled its latest insights in the 2025 Air Hacks Report, revealing strategies to help travelers save significantly on airfares. This report shatters several common myths about air travel, providing travelers with actionable advice to enjoy their journeys without breaking the bank. Understanding the...

Continue Reading
Blackmer Introduces Revolutionary Hydraulic Adapter Kit for Gas Compressors

Updated Category News Views 121

Blackmer's New Hydraulic Adapter Kit Revolutionizes Gas Compression In an exciting development within the compressor technology sector, Blackmer has unveiled its latest innovation: the Hydraulic Adapter Kit. This kit is designed for upgrading the leading LB080 and LB160 Series Reciprocating Gas Compressors, marking a significant advancement in mobile liquid petroleum gas...

Continue Reading
Understanding Shareholder Rights for PRO, IMXI, and TCBX

Updated Category News Views 125

Exploring Shareholder Rights and Options Halper Sadeh LLC, a law firm dedicated to protecting investor rights, is currently investigating several companies for potential breaches of fiduciary duties and violations of federal securities laws. The focus is on the rights of shareholders as specific companies undergo significant mergers and acquisitions. Recent Transactions...

Continue Reading
InMode Secures Court Ruling to Combat Counterfeit Morpheus8 Sales

Updated Category News Views 246

InMode Takes Legal Action Against Counterfeit Sales InMode Ltd. (NASDAQ: INMD), a prominent name in medical technology, has successfully secured a preliminary injunction from the U.S. District Court, aimed at safeguarding its renowned Morpheus8 radiofrequency devices and related accessories from counterfeit sales. This decision marks a significant victory in InMode's...

Continue Reading